Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

Chest

Volumn 132, Issue 3 SUPPL., 2007, Pages 69S-77S

  Bach, Peter B ^a   Silvestri, Gerard A ^b   Hanger, Morgan ^a   Jett, James R ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Biomolecular markers; Chest radiograph; Low dose CT; Lung cancer screening; Sputum cytology

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HIGH RISK POPULATION; HUMAN; LOW ENERGY RADIATION; LUNG CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; ARTICLE; COST BENEFIT ANALYSIS; CYTOLOGY; ECONOMICS; EVIDENCE BASED MEDICINE; LUNG TUMOR; MASS SCREENING; METHODOLOGY; PATHOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SPUTUM;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; MASS SCREENING; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848866957     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1349     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society, 2007
2. Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of the current literature. Chest 2003; 123(suppl):72S-82S
3. Black C, Bagust A, Boland A, et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 2006; 10:iii-iv, ix-x, 1-90
4. Jett JR, Midthun DE. Screening for lung cancer: current status and future directions; Thomas A. Neff lecture. Chest 2004; 125(suppl):158S-162S
5. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92:1308-1316
6. Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer 2000; 89(suppl):2363-2368
7. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 1979; 73:1-17
8. Spratt JS, Spratt JA. The prognostic value of measuring the gross linear radial growth of pulmonary metastases and primary pulmonary cancers. J Thorac Cardiovasc Surg 1976; 71:274-278
9. Wisnivesky JP, Bonomi M, Henschke C, et al. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest 2005; 128:1461-1467
10. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519
11. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294:1505-1510
12. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323-329
13. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000; 73:1252-1259
14. Yankelevitz DF, Kostis WJ, Henschke CI, et al. Overdiagnosis in chest radiographic screening for lung carcinoma: frequency. Cancer 2003; 97:1271-1275
15. Marshall D, Simpson KN, Earle CC, et al. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 2001; 32:227-236
16. Wisnivesky JP, Mushlin AI, Sicherman N, et al. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest 2003; 124:614-621
17. Marshall D, Simpson KN, Earle CC, et al. Economic decision analysis model of screening for lung cancer. Eur J Cancer 2001; 37:1759-1767
18. Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers; a decision and cost-effectiveness analysis. JAMA 2003; 289:313-322
19. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95:470-478
20. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226:756-761
21. Trial Info: Dutch Belgian randomised lung cancer screening trial (NELSON). Available at: http://www.trialregister.nl/trialreg/admin/rctview.asp? TC=636. Accessed August 21, 2007
22. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235:259-265
23. Patz EF Jr, Swensen SJ, Herndon JE II. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. J Clin Oncol 2004; 22:2202-2206
24. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763-1771
25. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: Anti-Lung Cancer Association Project. J Clin Oncol 2002; 20:911-920
26. Manser RL, Irving LB, Byrnes G, et al. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax 2003; 58:784-789
27. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4:707-717
28. McWilliams A, Mayo J, MacDonald S, et al. Lung cancer screening: a different paradigm. Am J Respir Crit Care Med 2003; 168:1167-1173
29. Phillips M, Cataneo RN, Cummin AR, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003; 123:2115-2123
30. Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999; 353:1930-1933
31. Carpagnano GE, Foschino-Barbaro MP, Mule G, et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med 2005; 172:738-744
32. Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005; 171:1286-1291
33. Petricoin EF, Liotta LA. Clinical applications of proteomics. J Nutr 2003; 133(suppl):2476S-2484S
34. Zhong L, Hidalgo GE, Stromberg AJ, et al. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 2005; 172:1308-1314
35. Jamshedur Rahman SM, Shyr Y, Yildiz PB, et al. Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med 2005; 172:1556-1562
36. Petricoin EF, Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol Med 2004; 10:59-64
37. Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002; 223:798-805
38. Chapman BE, Yankelevitz DF, Henschke CI, et al. Lung cancer screening: simulations of effects of imperfect detection on temporal dynamics. Radiology 2005; 234:582-590
39. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for early detection of cancer, 2005. CA Cancer J Clin 2005; 55:31-44
40. Aberle D, Gamsu G, Henschke C, et al. A consensus statement of the Society of Thoracic Radiology: screening for lung cancer with helical computed tomography. J Thorac Imaging 2001; 16:65-68
41. Chirikos TN, Hazelton T, Tockman M, et al. Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest 2002; 121:1507-1514